Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2006 1
2008 1
2014 2
2018 1
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Paralytic ileus associated with capecitabine.
Laudadio L, Biondi E, D'Ostilio N, Cesta A, Di Giandomenico F, Forciniti S, Nuzzo A. Laudadio L, et al. Among authors: biondi e. Tumori. 2008 Sep-Oct;94(5):742-5. doi: 10.1177/030089160809400517. Tumori. 2008. PMID: 19112951
Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.
Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, Martignetti A. Palmieri G, et al. Among authors: biondi e. Am J Clin Oncol. 2002 Jun;25(3):224-6. doi: 10.1097/00000421-200206000-00003. Am J Clin Oncol. 2002. PMID: 12040276 Clinical Trial.
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.
Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M. Ruzzo A, et al. Among authors: biondi e. Sci Rep. 2019 Aug 8;9(1):11527. doi: 10.1038/s41598-019-47627-1. Sci Rep. 2019. PMID: 31395900 Free PMC article. Clinical Trial.
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.
Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M. Ruzzo A, et al. Among authors: biondi e. Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828. Sci Rep. 2014. PMID: 25370899 Free PMC article. Clinical Trial.
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.
Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M. Ruzzo A, et al. Among authors: biondi e. Sci Rep. 2020 Jan 31;10(1):1918. doi: 10.1038/s41598-020-58486-6. Sci Rep. 2020. PMID: 32005869 Free PMC article.
Developing a decision-making model based on an interdisciplinary oncological care group for the management of colorectal cancer.
Genovesi D, Mazzilli L, Trignani M, DI Tommaso M, Nuzzo A, Biondi E, Tinari N, Martino MT, Innocenti P, DI Sebastiano P, Mazzola L, Lanci C, Neri M, Laterza F, Marino M, Ferrini G, Spadaccini A, Filippone A, DI Giandomenico E, Marulli A, Palombo G, Sparvieri A, Marchetti A, Pizzicannella G, Petrini F, DI Felice M, Ottaviani F, Monteodorisio A, DI Nicola M, Cefaro GA. Genovesi D, et al. Among authors: biondi e. Anticancer Res. 2014 May;34(5):2525-31. Anticancer Res. 2014. PMID: 24778070
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.